Detection of Endogenous Selective Estrogen Receptor Modulators such as 27-Hydroxycholesterol

Part of the Methods in Molecular Biology book series (MIMB, volume 1366)

Abstract

The estrogen receptors (ERs) belong to the nuclear receptor superfamily, and as such act as ligand inducible transcription factors, mediating the effects of estrogens. However, their pharmacology is complex, having the ability to be differentially activated by ligands. Such ligands possess the ability to behave as either ER-agonists or ER-antagonists, depending on the cellular and tissue context, and have been termed Selective Estrogen Receptor Modulators (SERMs). Several SERMs have been identified with clinical relevance such as tamoxifen and raloxifene. Recently, 27-hydroxycholesterol has been characterized as the first identified endogenous SERM leading to the notion that other endogenous SERMs may exist, each having potential pathophysiological functions. This, coupled with the historic pharmaceutical interest as well as growing concern over chemicals in the environment with the ability to behave like SERMs, has increased the demand for assays to detect SERM-like activity. Here, we describe a common, straightforward in vitro assay investigating the induction of classic ER-target genes in MCF7 breast cancer cells, allowing one to identify ligands with SERM-like activity.

Key words

Estrogenreceptor Selective estrogen receptor modulator (SERM) Estradiol 27-Hydroxycholesterol Tamoxifen Gene expression Quantitative PCR MCF7 cells Pharmacology 

References

  1. 1.
    Green S, Walter P, Kumar V et al (1986) Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature 320:134–139CrossRefPubMedGoogle Scholar
  2. 2.
    Kuiper GG, Enmark E, Pelto-Huikko M et al (1996) Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A 93:5925–5930CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Couse JF, Lindzey J, Grandien K et al (1997) Tissue distribution and quantitative analysis of estrogen receptor-alpha (ERalpha) and estrogen receptor-beta (ERbeta) messenger ribonucleic acid in the wild-type and ERalpha-knockout mouse. Endocrinology 138:4613–4621CrossRefPubMedGoogle Scholar
  4. 4.
    Maximov PY, Lee TM, Jordan VC (2013) The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice. Curr Clin Pharmacol 8:135–155CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Hall JM, McDonnell DP (1999) The estrogen receptor β-isoform (ERβ) of the human estrogen receptor modulates ERα transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 140:5566–5578CrossRefPubMedGoogle Scholar
  6. 6.
    Hall JM, McDonnell DP (2005) Coregulators in nuclear estrogen receptor action: from concept to therapeutic targeting. Mol Interv 5:343–357CrossRefPubMedGoogle Scholar
  7. 7.
    Bjornstrom L, Sjoberg M (2005) Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol Endocrinol 19:833–842CrossRefPubMedGoogle Scholar
  8. 8.
    Lonard DM, O’Malley BW (2012) Nuclear receptor coregulators: modulators of pathology and therapeutic targets. Nat Rev Endocrinol 8:598–604CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Cheskis BJ, Greger JG, Nagpal S et al (2007) Signaling by estrogens. J Cell Physiol 213:610–617CrossRefPubMedGoogle Scholar
  10. 10.
    Improta-Brears T, Whorton AR, Codazzi F et al (1999) Estrogen-induced activation of mitogen-activated protein kinase requires mobilization of intracellular calcium. Proc Natl Acad Sci U S A 96:4686–4691CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    DuSell CD, Umetani M, Shaul PW et al (2008) 27-hydroxycholesterol is an endogenous selective estrogen receptor modulator. Mol Endocrinol 22:65–77CrossRefPubMedGoogle Scholar
  12. 12.
    Lappano R, Recchia AG, De Francesco EM et al (2011) The cholesterol metabolite 25-hydroxycholesterol activates estrogen receptor alpha-mediated signaling in cancer cells and in cardiomyocytes. PLoS One 6:e16631CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Umetani M, Domoto H, Gormley AK et al (2007) 27-Hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen. Nat Med 13:1185–1192CrossRefPubMedGoogle Scholar
  14. 14.
    Umetani M, Ghosh P, Ishikawa T et al (2014) The cholesterol metabolite 27-hydroxycholesterol promotes atherosclerosis via proinflammatory processes mediated by estrogen receptor alpha. Cell Metab 20:172–182CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    DuSell CD, Nelson ER, Wang X et al (2010) The endogenous selective estrogen receptor modulator 27-hydroxycholesterol is a negative regulator of bone homeostasis. Endocrinology 151:3675–3685CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Nelson ER, Dusell CD, Wang X et al (2011) The oxysterol, 27-hydroxycholesterol, links cholesterol metabolism to bone homeostasis through its actions on the estrogen and liver x receptors. Endocrinology 152:4691–4705CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Nelson ER, Wardell SE, Jasper JS et al (2013) 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science 342:1094–1098CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Wu Q, Ishikawa T, Sirianni R et al (2013) 27-Hydroxycholesterol promotes cell-autonomous, ER-positive breast cancer growth. Cell Rep 5:637–645CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Kuiper GG, Carlsson B, Grandien K et al (1997) Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 138:863–870CrossRefPubMedGoogle Scholar
  20. 20.
    Norris JD, Paige LA, Christensen DJ et al (1999) Peptide antagonists of the human estrogen receptor. Science 285:744–746CrossRefPubMedGoogle Scholar
  21. 21.
    Norris JD, Joseph JD, Sherk AB et al (2009) Differential presentation of protein interaction surfaces on the androgen receptor defines the pharmacological actions of bound ligands. Chem Biol 16:452–460CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Wardell SE, Kazmin D, McDonnell DP (2012) Research resource: transcriptional profiling in a cellular model of breast cancer reveals functional and mechanistic differences between clinically relevant SERM and between SERM/estrogen complexes. Mol Endocrinol 26:1235–1248CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156–159CrossRefPubMedGoogle Scholar
  24. 24.
    Nelson ER, Habibi HR (2008) Functional significance of a truncated thyroid receptor subtype lacking a hormone-binding domain in goldfish. Endocrinology 149:4702–4709CrossRefPubMedGoogle Scholar
  25. 25.
    Wardell SE, Nelson ER, Chao CA et al (2013) Bazedoxifene exhibits antiestrogenic activity in animal models of tamoxifen-resistant breast cancer: implications for treatment of advanced disease. Clin Cancer Res 19:2420–2431CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Wright TM, Wardell SE, Jasper JS et al (2014) Delineation of a FOXA1/ERalpha/AGR2 regulatory loop that is dysregulated in endocrine therapy-resistant breast cancer. Mol Cancer Res 12:1829–1839CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Department of Molecular and Integrative PhysiologyUniversity of Illinois at Urbana-ChampaignUrbanaUSA

Personalised recommendations